These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 19967149

  • 1. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment.
    Undas A, Kaczmarek P, Sladek K, Stepien E, Skucha W, Rzeszutko M, Gorkiewicz-Kot I, Tracz W.
    Thromb Haemost; 2009 Dec; 102(6):1176-82. PubMed ID: 19967149
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality.
    Undas A, Kolarz M, Kopeć G, Tracz W.
    Nephrol Dial Transplant; 2008 Jun; 23(6):2010-5. PubMed ID: 18156458
    [Abstract] [Full Text] [Related]

  • 4. The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome.
    Undas A, Nycz K, Pastuszczak M, Stompor T, Zmudka K.
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):522-7. PubMed ID: 20479639
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients.
    Panichi V, Paoletti S, Mantuano E, Manca-Rizza G, Filippi C, Santi S, Taccola D, Donadio C, Tramonti G, Innocenti M, Casto G, Consani C, Sbragia G, Franzoni F, Galetta F, Panicucci E, Barsotti G.
    Nephrol Dial Transplant; 2006 Feb; 21(2):337-44. PubMed ID: 16249194
    [Abstract] [Full Text] [Related]

  • 7. Fibrin clot structure in patients with end-stage renal disease.
    Sjøland JA, Sidelmann JJ, Brabrand M, Pedersen RS, Pedersen JH, Esbensen K, Standeven KF, Ariëns RA, Gram J.
    Thromb Haemost; 2007 Aug; 98(2):339-45. PubMed ID: 17721616
    [Abstract] [Full Text] [Related]

  • 8. Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation.
    Celińska-Lowenhoff M, Iwaniec T, Padjas A, Musiał J, Undas A.
    Thromb Haemost; 2014 Aug; 112(2):287-96. PubMed ID: 24652596
    [Abstract] [Full Text] [Related]

  • 9. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease.
    van Gestel YR, Hoeks SE, Sin DD, Simsek C, Welten GM, Schouten O, Stam H, Mertens FW, van Domburg RT, Poldermans D.
    Am J Cardiol; 2008 Jul 15; 102(2):192-6. PubMed ID: 18602520
    [Abstract] [Full Text] [Related]

  • 10. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress.
    Undas A, Szułdrzynski K, Stepien E, Zalewski J, Godlewski J, Tracz W, Pasowicz M, Zmudka K.
    Atherosclerosis; 2008 Feb 15; 196(2):551-7. PubMed ID: 17640649
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l.
    Undas A, Topór-Madry R, Tracz W.
    Pol Arch Med Wewn; 2009 Jun 15; 119(6):354-9. PubMed ID: 19694216
    [Abstract] [Full Text] [Related]

  • 13. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin.
    Lee TM, Lin MS, Chang NC.
    Am J Cardiol; 2008 Feb 15; 101(4):530-5. PubMed ID: 18312772
    [Abstract] [Full Text] [Related]

  • 14. Factor XIII Val34Leu polymorphism as a modulator of fibrin clot permeability and resistance to lysis in patients with severe coronary artery disease.
    Stepień E, Plicner D, Kapelak B, Wypasek E, Sadowski J, Undas A.
    Kardiol Pol; 2009 Aug 15; 67(8A):947-55. PubMed ID: 19784898
    [Abstract] [Full Text] [Related]

  • 15. Hyperhomocysteinaemia and poor vitamin B status in chronic obstructive pulmonary disease.
    Fimognari FL, Loffredo L, Di Simone S, Sampietro F, Pastorelli R, Monaldo M, Violi F, D'Angelo A.
    Nutr Metab Cardiovasc Dis; 2009 Nov 15; 19(9):654-9. PubMed ID: 19282159
    [Abstract] [Full Text] [Related]

  • 16. Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
    Mastalerz L, Celińska-Lӧwenhoff M, Krawiec P, Batko B, Tłustochowicz W, Undas A.
    PLoS One; 2015 Nov 15; 10(11):e0142167. PubMed ID: 26540111
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Altered fibrin clot properties in patients with chronic heart failure and sinus rhythm: a novel prothrombotic mechanism.
    Palka I, Nessler J, Nessler B, Piwowarska W, Tracz W, Undas A.
    Heart; 2010 Jul 15; 96(14):1114-8. PubMed ID: 20610458
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans.
    Undas A, Nowakowski T, Cieśla-Dul M, Sadowski J.
    Atherosclerosis; 2011 Apr 15; 215(2):481-6. PubMed ID: 21324459
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.